STVN

Business Context and Reporting Period

Company: Stevanato Group S.P.A.
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and six months ended June 30, 2025
Business Overview: A global provider of drug containment, drug delivery, and diagnostic solutions. The Group operates two segments: Biopharmaceutical and Diagnostic Solutions (high-value solutions like EZ-Fill® and standard containment) and Engineering (machinery and equipment). The company is currently expanding capacity in Fishers, Indiana (USA) and Latina (Italy) while slowing expansion in China.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 7.9% (Q2) and 8.3% (H1) year-over-year, driven primarily by the Biopharmaceutical and Diagnostic Solutions segment. High-value solutions now represent 42.3% of total revenue (H1 2025) compared to 38.6% in H1 2024.
• Profitability Expansion: Operating profit surged 47.9% in Q2 and 42.7% in H1. This was fueled by improved gross margins in the Biopharmaceutical segment (31.2% in H1 2025 vs. 27.4% in H1 2024) due to a higher mix of high-value products and improved performance at new facilities.
• Engineering Segment Pressure: The Engineering segment reported a decline in revenue and margins (Gross margin 8.8% in H1 2025 vs. 13.8% in H1 2024) due to an unfavorable project mix and legacy project costs.
• Foreign Exchange Impact: Significant net foreign exchange losses of EUR 13.6 million in H1 2025 (vs. a gain of EUR 4.2 million in H1 2024) negatively impacted finance expenses, primarily due to the depreciation of the U.S. Dollar against the Euro.
• Cost Management: R&D expenses decreased significantly (38.6% in H1) due to right-sizing and project optimization. Restructuring charges were lower in 2025 compared to 2024.

Guidance, Outlook, and Risks

• Capacity Expansion: The Group is ramping up production at new facilities in Fishers, Indiana, and Latina, Italy. Commercial production in Fishers began in Q3 2024, with further lines expected through 2025 and 2026. The China facility in Zhangjiagang is being sold via a rent-to-buy agreement to focus resources on U.S. and Italian expansion.
• Market Recovery: Management expects a gradual recovery in demand for glass vials as customers destock inventories accumulated during the pandemic.
• Tax Benefits: The effective tax rate decreased to 24.3% in H1 2025 (from 28.1% in H1 2024) due to the "IRES premiale" tax benefit in Italy, which reduces the corporate tax rate to 20% for 2025 if investment and labor requirements are met.
• Internal Controls: The Company disclosed that its internal controls over financial reporting were not effective as of December 31, 2024, due to material weaknesses. Remediation efforts are ongoing, including enhanced business process controls and IT general controls.
• Risks: Key risks include foreign currency fluctuations, supply chain challenges, customer destocking, and the successful ramp-up of new manufacturing lines to achieve target productivity.

Investor Verification Checklist

• High-Value Mix Sustainability: Verify if the shift toward high-margin "high-value solutions" (syringes, EZ-Fill®) is sustainable or driven by temporary customer demand spikes.
• Engineering Turnaround: Monitor the Engineering segment's ability to return to profitable growth following the optimization plan and project mix challenges.
• FX Hedging Effectiveness: Assess the impact of continued USD/EUR volatility on future earnings, given the significant translation losses in H1 2025.
• Internal Control Remediation: Confirm the timeline and success of remediation efforts for the previously disclosed material weaknesses in internal controls.
• Capital Expenditure Execution: Track the progress of the EUR 127 million in committed orders for new facilities and the associated cash burn vs. revenue generation.